HealthcareServices

Ocular Genetic Diagnostic Industry Anticipated to Expand at 9.4% CAGR During the Forecast Period

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Ocular Genetic Diagnostic Market By 2029?

The ocular genetic diagnostics market has experienced robust expansion in recent years. It is projected to increase from $0.98 billion in 2024 to $1.07 billion by 2025, at a compound annual growth rate (CAGR) of 9.7%. This growth over the historic period can be ascribed to factors such as the early adoption of molecular diagnostic techniques, a heightened awareness of inherited eye disorders, the expansion of academic and clinical research, an escalating incidence of retinal dystrophies, and a significant rise in demand for pediatric genetic testing.

The ocular genetic diagnostics market size is anticipated to undergo significant expansion in the coming years. By 2029, it is projected to reach $1.53 billion, demonstrating a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period is fueled by several factors, including the increasing need for personalized ophthalmic care, the wider availability of direct-to-consumer genetic tests, greater investment in gene therapy trials, the advancement of precision medicine initiatives, and the incorporation of artificial intelligence in interpreting genetic data. Noteworthy trends expected during this period encompass the rising utilization of artificial intelligence-powered genetic analysis, the proliferation of at-home genetic testing kits, an escalating demand for prenatal ocular genetic screening, the creation of gene-specific diagnostic platforms, and progress in cloud-based genetic data storage.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28283&type=smp

Which Industry Drivers Are Expected To Accelerate The Ocular Genetic Diagnostic Market From 2025 To 2029?

The future expansion of the ocular genetic diagnostic market is anticipated to be driven by the rising incidence of eye diseases. These diseases are various medical conditions impacting the eye’s structure or how it functions, which can result in impaired vision or blindness if left unaddressed. The increase in eye diseases is largely attributable to greater screen time and digital device usage, contributing to eye strain, dry eye, and other vision problems. Ocular genetic diagnostics offers advantages for eye diseases by enabling early detection of inherited genetic factors, providing better understanding of disease origins, and assisting in more accurate diagnosis and treatment. For example, a survey conducted in February 2025 by the American Foundation for the Blind, a US-based organization dedicated to individuals with vision loss, revealed that 51.9 million American adults aged 18 and older reported experiencing some degree of vision difficulty. Of these, 3.7 million faced significant challenges seeing even with corrective lenses, and 307,000 were entirely blind. The remaining 47.9 million indicated mild vision issues despite wearing glasses. Consequently, the growing prevalence of eye diseases is fueling the development of the ocular genetic diagnostic market.

What Are The Emerging Segments Gaining Attention In The Ocular Genetic Diagnostic Market?

The ocular genetic diagnostic market covered in this report is segmented as

1) By Test Type: Single Gene Testing, Panel Testing, Whole Exome Sequencing, Whole Genome Sequencing

2) By Technology Type: Sequencing Technology, Polymerase Chain Reaction (PCR), Microarray Technology, Next-Generation Sequencing (NGS)

3) By Application: Retinal Disorders, Cataract Diagnosis, Inherited Ocular Disorders, Age-Related Macular Degeneration

4) By End User: Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End Users

Subsegments:

1) By Single Gene Testing: Retinoblastoma Gene Testing (RB1), RPE65 Gene Mutation Testing, MYOC Gene Testing (Glaucoma), OPA1 Gene Testing (Optic Atrophy), BEST1 Gene Testing (Best Disease)

2) By Panel Testing: Inherited Retinal Disease (IRD) Panels, Glaucoma Genetic Panels, Macular Dystrophy Panels, Optic Neuropathy Panels, Syndromic Ocular Disorder Panels

3) By Whole Exome Sequencing (WES): Trio Exome Sequencing, Diagnostic Exome Sequencing, Exome Reanalysis Services, Rapid Exome Testing, Prenatal Exome Sequencing

4) By Whole Genome Sequencing (WGS): Clinical Whole Genome Sequencing, Rapid Whole Genome Sequencing, Pediatric Genome Sequencing, Prenatal Whole Genome Sequencing, Ultra-Rare Eye Disease Genome Sequencing

What Are The Latest Industry Trends Transforming The Ocular Genetic Diagnostic Market?

Leading companies operating within the ocular genetic diagnostic market are concentrating on developing advanced offerings, such as clinical services, to improve early identification, diagnostic accuracy, and personalized treatment for inherited eye diseases. A clinical service is a healthcare activity provided by professionals to evaluate, diagnose, treat, and manage the health conditions of patients. For instance, in October 2024, the Singapore National Eye Centre (SNEC), a Singapore-based public-sector specialty eye hospital, launched the Ocular Genetics Service (OGS), a clinical service intended to provide specialized care for patients with hereditary eye conditions. This dedicated service consolidates genetic testing, counselling, and tailored clinical management under one roof, ensuring timely diagnosis and intervention for rare genetic eye conditions. By integrating multidisciplinary expertise, the OGS boosts diagnostic precision and allows patients to access personalized care plans based on their genetic profile. Such introductions of clinical services demonstrate a broader trend in the ocular genetic diagnostics market favoring precision medicine and comprehensive, patient-centered care models.

Who Are The Top Performing Companies In The Ocular Genetic Diagnostic Market In Recent Years?

Major companies operating in the ocular genetic diagnostic market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Illumina Inc., The Children’s Hospital of Philadelphia, University of Iowa Hospitals and Clinics, PerkinElmer Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., ARUP Laboratories Inc., Invitae Corporation, Spark Therapeutics Inc., GeneDx LLC, Blueprint Genetics Oy, Medgenome Labs Inc., Centogene NV, PreventionGenetics LLC, Molecular Vision Laboratory LLC, Casey Eye Institute, and Moorfields Eye Hospital & UCL Institute of Ophthalmology.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report

What Regional Growth Trends Are Shaping The Ocular Genetic Diagnostic Market Outlook?

North America was the largest region in the ocular genetic diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ocular genetic diagnostic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Ocular Genetic Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28283&type=smp

Browse Through More Reports Similar to the Global Ocular Genetic Diagnostic Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Dry Eye Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report

Ocular Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795